{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:20:52Z","timestamp":1783693252785,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007560","name":"Chiesi Pharmaceuticals SpA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clinthera.2026.04.009","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:06:48Z","timestamp":1778584008000},"page":"757-763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Switching to a Low Global Warming Potential Propellant in a Pressurized Metered-Dose Inhaler Does Not Affect the Pharmacokinetics of Combined Beclometasone Dipropionate\/Formoterol Fumarate"],"prefix":"10.1016","volume":"48","author":[{"given":"Mafalda","family":"Almeida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Salvadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Corradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"De Ridder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Praet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Viaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Varoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Girardello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glauco","family":"Cappellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca V.","family":"Vigan\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kusum S.","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.04.009_bib0001","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11367-021-01998-8","article-title":"Environmental footprint of regular and intensive inpatient care in a large US hospital","volume":"27","author":"Prasad","year":"2022","journal-title":"Int J Life Cycle Assess"},{"key":"10.1016\/j.clinthera.2026.04.009_bib0002","doi-asserted-by":"crossref","first-page":"00577","DOI":"10.1183\/23120541.00577-2023","article-title":"Environmental, healthcare and societal impacts of asthma: a UK model-based assessment","volume":"10","author":"Orlovic","year":"2024","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.clinthera.2026.04.009_bib0003","series-title":"Amendment to the Montreal Protocol on Substances That Deplete the Ozone Layer","year":"2016"},{"key":"10.1016\/j.clinthera.2026.04.009_bib0004","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.2147\/DDDT.S262141","article-title":"The climate is changing for metered-dose inhalers and action is needed","volume":"14","author":"Pritchard","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clinthera.2026.04.009_bib0005","unstructured":"European Union. Regulation (EU) 2024\/573 of the European Parliament and of the Council of 7 February 2024 on fluorinated greenhouse gases, amending Directive (EU) 2019\/1937 and repealing Regulation (EU) No 517\/2014 (Text with EEA relevance). 2024. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=OJ:L_202400573, Accessed May 5, 2026."},{"key":"10.1016\/j.clinthera.2026.04.009_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2025.102356","article-title":"Impact on beclometasone dipropionate pharmacokinetics when switching to a low global warming potential propellant in a pressurised metered-dose inhaler","volume":"89","author":"Rony","year":"2025","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.04.009_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2024.102299","article-title":"Evaluating the pharmacokinetics of beclometasone dipropionate\/formoterol fumarate\/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellant","volume":"85","author":"Rony","year":"2024","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.04.009_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2025.102358","article-title":"The low global warming potential propellant HFA-152a does not induce bronchoconstriction or impair mucociliary clearance","volume":"89","author":"Salvadori","year":"2025","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.04.009_bib0009","series-title":"Guideline on the Requirements for Demonstrating Therapeutic Equivalence Between Orally Inhaled Products (OIP) for Asthma and Chronic Obstructive Pulmonary Disease (COPD) (CPMP\/EWP\/4151\/00 Rev. 2)","year":"2025"},{"key":"10.1016\/j.clinthera.2026.04.009_bib0010","unstructured":"Chiesi Limited. Fostair 100\/6 Inhalation Solution: Summary of Product Characteristics. 2023."},{"key":"10.1016\/j.clinthera.2026.04.009_bib0011","unstructured":"Chiesi Limited. Fostair 200\/6 Micrograms Per Actuation Pressurised Inhalation Solution. 2023."},{"key":"10.1016\/j.clinthera.2026.04.009_bib0012","series-title":"Guideline on the Investigation of Bioequivalence","year":"2010"},{"key":"10.1016\/j.clinthera.2026.04.009_bib0013","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.0306-5251.2001.01374.x","article-title":"Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man","volume":"51","author":"Daley-Yates","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.04.009_bib0014","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s002280050607","article-title":"Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer","volume":"55","author":"Lecaillon","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.04.009_bib0015","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","article-title":"Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial","volume":"388","author":"Singh","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2026.04.009_bib0016","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(17)30188-5","article-title":"Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial","volume":"389","author":"Vestbo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2026.04.009_bib0017","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2026.04.009_bib0018","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0140-6736(19)32215-9","article-title":"Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials","volume":"394","author":"Virchow","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2026.04.009_bib0019","unstructured":"Chiesi Farmaceutici SpA. Comparison between CHF5993 pMDI 200\/6\/12.5 \u00b5g HFA-152a vs CHF5993 pMDI 200\/6\/12.5 \u00b5g HFA-134a in subjects with asthma (TRECOS) (NCT06264674). n.d. https:\/\/clinicaltrials.gov\/study\/NCT06264674?term=NCT06264674&rank=1. Accessed February 25, 2026."},{"key":"10.1016\/j.clinthera.2026.04.009_bib0020","series-title":"Abstract Presented at 34th Annual Drug Delivery to the Lungs Congress","article-title":"Overview of the nonclinical safety program for 1,1-difluoroethane (HFA-152a) as a low global warming potential metered dose inhaler propellant","author":"Mohar","year":"2023"},{"key":"10.1016\/j.clinthera.2026.04.009_bib0021","first-page":"87","article-title":"Safety, tolerance and pharmacokinetics of HFA-152a in healthy volunteers","volume":"2022","author":"Kuehl","year":"2022","journal-title":"Respir Drug Deliv"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826001128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826001128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:03:20Z","timestamp":1783692200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826001128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0149291826001128"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.04.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching to a Low Global Warming Potential Propellant in a Pressurized Metered-Dose Inhaler Does Not Affect the Pharmacokinetics of Combined Beclometasone Dipropionate\/Formoterol Fumarate","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}